Treatment Advancements in Anemia in Chronic Kidney Disease: Assessing HIF-PH Inhibitors

Program Description

Chronic kidney disease (CKD) is associated with substantial burden for patients. A greater understanding of the pathophysiology of anemia in CKD and the need for alternative therapy in patients unable to respond to iron therapy or erythropoiesis-stimulating agents has led to new treatment targets focusing on inhibiting the hypoxia-inducible factor pathway. This podcast will focus on emerging and investigational hypoxia-inducible factor prolyl hydroxylase inhibitors and the recent data updates. Key counseling points and considerations for pharmacists in the multidisciplinary management of treatment strategies for patients with anemia in CKD will be discussed.

Target audience: Health-system, retail, and specialty pharmacists

Type of activity: Application
Release date: August 31, 2022
Expiration date: August 31, 2023

Time to complete activity: 0.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Outline updates and advancements in the development of HIF-PH inhibitors for anemia in chronic kidney disease
• Express the role of the pharmacist in managing anemia in CKD through early detection and coordination of care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-417-H01-P. The activity is available for CE credit through August 31, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joanna Q Hudson, Pharm.D., BCPS, FASN, FCCP, FNKF has the following financial relationships with commercial interests to disclose:
Consultant: Bayer

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jessica L. Kerr, PharmD, CDCES

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, MBA, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms